

# The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).

<b>Submission date</b> 17/02/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 21/02/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 03/08/2007	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr David Schriger

### Contact details

924 Westwood Blvd Suite 300

Los Angeles, CA

United States of America

90024-2924

+1 310 794 0593

[schriger@ucla.edu](mailto:schriger@ucla.edu)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

## Scientific Title

## Acronym

UCLA PRIME MD-2

## Study objectives

Not provided at time of registration.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration.

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Diagnostic

## Participant information sheet

## Health condition(s) or problem(s) studied

Depression, anxiety and other psychiatric conditions

## Interventions

Patients take the computerized PRIME-MD in the ED waiting room. They are randomized to three groups: PRIME-MD results shared with no one, shared with the patient only, or shared with the patient and the treating ED physician.

Low cost/no cost psychiatric referral sheet made available in the ED.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Not provided at time of registration.

**Secondary outcome measures**

Not provided at time of registration.

**Overall study start date**

01/03/2002

**Completion date**

01/09/2002

## **Eligibility**

**Key inclusion criteria**

ED patients who present with a somatic (non-psychiatric) complaint that is of long duration, is chronic, or is not of a severity to warrant emergency care.  
Resident physicians in Emergency Medicine and their faculty.

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration.

**Key exclusion criteria**

Not provided at time of registration.

**Date of first enrolment**

01/03/2002

**Date of final enrolment**

01/09/2002

## **Locations**

**Countries of recruitment**

United States of America

**Study participating centre**

**924 Westwood Blvd Suite 300**  
Los Angeles, CA  
United States of America  
90024-2924

## **Sponsor information**

### **Organisation**

University of California, Los Angeles (UCLA) (USA)

### **Sponsor details**

924 Westwood Blvd Suite 300  
Los Angeles, CA  
United States of America  
90024 2924

### **Sponsor type**

University/education

### **ROR**

<https://ror.org/046rm7j60>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

The Pfizer Corporation provided a \$60,000 gift (not grant) in support of this research.

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	09/05/2005		Yes	No